A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

Dr. Li Li shares why annual skin checks with advanced tech like mole mapping are essential for skin cancer prevention.

Low-grade systemic inflammation is an independent risk factor for psoriasis, especially moderate to severe disease, results ...